FMP
Akouos, Inc.
AKUS
NASDAQ
Inactive Equity
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
13.29 USD
0 (0%)
AKUS Financial Statements
Quarter
2022 Q3
2022 Q2
2022 Q1
2021 Q4
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
20.2M
21M
27.03M
24.98M
Research and Development
13.94M
14.32M
20.39M
18.82M
Selling, General & Administrative Expenses
6.27M
6.68M
6.65M
6.16M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
6.27M
6.68M
6.65M
6.16M
Other Expenses
0
0
0
0
Operating Income
-19.32M
-20.83M
-26.73M
-24.94M
Total Other Income/Expenses Net
365k
169k
51k
38k
Income Before Tax
-19.84M
-20.83M
-26.98M
-24.94M
Income Tax
522k
169k
257k
38k
Net Income
-20.36M
-20.83M
-27.24M
-24.94M
Basic EPS
-0.55
-0.58
-0.79
-0.72
EPS Diluted
-0.55
-0.58
-0.79
-0.72
Basic Average Shares
36.91M
35.84M
34.53M
34.47M
Diluted Average Shares
36.91M
35.84M
34.53M
34.47M
EBITDA
-18.29M
-19.42M
-25.8M
-23.91M
All figures are in USD.
